Marshall Wace
ELOS

Marshall Wace’s Syneron Medical Ltd ELOS Stock Holding History

Marshall Wace’s Portfolio ELOS Stock Details ELOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-191,491
Closed -$1.47M – 1258
2016
Q2 		$1.47M Buy
+191,491
New +$1.37M 0.01% 652

Other funds holding ELOS

SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
NTC
North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
CAD
Craig A. Drill $24.4M AUM 13.42% 1-Year Est. Return
DGHMC
Dalton, Greiner, Hartman, Maher & Co New York $126M AUM 92.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
PCM
Perritt Capital Management Chicago, Illinois $59.8M AUM 26.94% 1-Year Est. Return

Marshall Wace's ELOS Position: Q3 2016 in Review

Marshall Wace sold out of Syneron Medical Ltd (ELOS) in Q3 2016, closing a stake of 191,491 shares — an estimated $1.47M sold.

Marshall Wace first reported a position in ELOS in Q2 2016 and held it in 1 quarter. The position peaked at $1.47M in Q2 2016. 65 funds tracked by Wall St. Rank hold ELOS as of Q3 2016.

  • Marshall Wace reported no remaining Syneron Medical Ltd position as of Q3 2016 after selling out during the quarter.
  • Marshall Wace sold 191,491 Syneron Medical Ltd shares in Q3 2016, an estimated $1.47M.
  • Marshall Wace first reported a position in Syneron Medical Ltd in Q2 2016 and held it in 1 quarter.
  • Marshall Wace's Syneron Medical Ltd position peaked at $1.47M in Q2 2016.
  • 65 funds tracked by Wall St. Rank held Syneron Medical Ltd as of Q3 2016.

Based on Marshall Wace's 13F filing for Q3 2016, filed 10 Nov 2016.